Poster: MPN-545 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs. Anagrelide as Second Line Therapy in Essential Thrombocythemia

Ruben Mesa,Norio Komatsu,Harinder Gill,Jie Jin,Sung-Eun Lee,Hsin-An Hou,Toshiaki Sato,Albert Qin,Raymond Urbanski,Weichung Shih,Oleh Zagrijtschuk,Craig Zimmerman,Srdan Verstovsek

Clinical Lymphoma Myeloma and Leukemia（2022）

引用 4|浏览1

暂无评分

摘要

Results will provide the first evidence of a second-line ET treatment by comparing P1101 with the only approved treatment option, ANA. This study is sponsored by PharmaEssentia USA.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要